About the Task Force
The FDA Nanotechnology Task Force (Task Force), formed in August 2006, was charged with determining regulatory approaches that encourage the continued development of innovative, safe, and effective FDA-regulated products that use nanotechnology or nanomaterials. The Task Force also identifies and recommends ways to address any knowledge or policy gaps that exist within the nanotechnology research community. Improved understanding better enables FDA to evaluate possible adverse health effects from FDA-regulated products that use nanotechnology or nanomaterials.
With the gradual increase in nanomaterial-containing product submissions to FDA, the Task Force encourages regulatory science research in nanotechnology through internal research grants. Additionally, the Task Force provides hands-on nanotechnology training to FDA reviewers and research staff to build scientific expertise and capacity. The Task Force members and subject matter experts at FDA also are active in international documentary nanotechnology standards development.
With a dedicated nanotechnology budget, FDA supports the National Nanotechnology Initiative (NNI) and collaborates with other agencies through participation in the Nanoscale Science Engineering and Technology (NSET) subcommittee and the Nanotechnology Environmental and Health Implications (NEHI) working group. FDA provides annual reports towards the President’s Budget supplement request.
The Task Force reports to the Chief Scientist, within the Office of the Commissioner, and its members are designated representatives from all FDA Centers and Offices.
Nanotechnology Task Force Reports
- FDA Nanotechnology Report Outlines Scientific, Regulatory Challenges [ARCHIVED]
- FDA Forms Internal Nanotechnology Task Force [ARCHIVED]
- FDA NanoDay Virtual Research Symposium, October 9, 2020 (virtual meeting recorded in Adobe Connect)
- FDA Nanotechnology Public Meeting September 8, 2008
- FDA Nanotechnology Public Meeting October 10, 2006